Johnson & Johnson Family of Companies
NEWS
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
Patients who took Taltz in the post-marketing study achieved higher rates of “complete skin clearance” in comparison to Tremfya as measured by PASI 100.
Specifically, the civil subpoenas were issued to determine if the company had violated antitrust laws with its rheumatoid arthritis drug Remicade.
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
It was a big week for Alzheimer’s research as researchers from around the world descended on Los Angeles to attend the Alzheimer’s Association International Conference (AAIC) this week. Here’s a look at some of the stories you may have missed.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
The beginning of July is when many companies increase the price on prescription medications in the U.S. This year’s price increases are higher than the same period last year.
JOBS
IN THE PRESS